⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JUNS News
Jupiter Neurosciences, Inc. Common Stock
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
globenewswire.com
JUNS
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
globenewswire.com
JUNS
Jupiter Neurosciences to Participate in NobleCon21
newsfilecorp.com
JUNS
Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
globenewswire.com
JUNS
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
globenewswire.com
JUNS
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
globenewswire.com
JUNS